Search Generic Medicine

Medicine Index

Search by generic name

Tag: Lung Cancer

Generic Lorlatinib

Lorlatinib is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually . . . Read more

Generic Selpercatinib

Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results . . . Read more

Generic Sotorasib

Sotorasib is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer. Sotorasib sold under the brand name Lumakras.There is no general version yet.

Generic Trametinib

Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Trametinib can be used in combination with Dabrafenib to treat people with a type of skin cancer called melanoma: That has spread to other parts of the body . . . Read more

Generic Dabrafenib

Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib  to treat certain types of cancer in people who have a “BRAF” gene mutation. dabrafenib is for use in treating: for the treatment of patients with unresectable or metastatic melanoma . . . Read more

Generic Capmatinib

Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation – via mutations, amplification, and/or overexpression – is known to occur in many . . . Read more

Generic Brigatinib

Brigatinib  is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in . . . Read more

Generic Alectinib

Alectinib is an anti-cancer  targeted therapy. It is classified as a tyrosine kinase inhibitor ALK (anaplastic lymphoma kinase) gene mutation. Alectinib is used to treat : ALK Positive NSCLC(Non-small cell lung cancer) ALK Positive ALCL(Anaplastic large-cell lymphoma ) Alectinib sold as brand name Alecensa.It has a generic form of several . . . Read more

Generic Ceritinib

Ceritinib is an oral ATP-competitive ALK and ROS1 TKI, but contrary to crizotinib does not have MET TKI activity, nevertheless may inhibit other receptors to a lesser extent such as the insulin-like growth factor 1 receptor (IGF-1) . In vitro, ceritinib inhibits ALK with a 20-fold greater potency than crizotinib, . . . Read more

Generic Crizotinib

Crizotinib is an inhibitor that makes minimal interactions with the ATP-binding pocket, and thus inhibits many kinases, including ALK、ROS1 and c-MET.  Crizotinib is used to treat : ALK Positive Non-Small Cell Lung Cancer (NSCLC) ROS1 Positive non-small cell lung cancer (NSCLC) ALK Positive Anaplastic large-cell lymphoma (ALCL) Crizotinib sold as . . . Read more